Patent Grant
11918624
The present invention is directed to a therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders.
The instant application contains a sequence listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jul. 9, 2020 is named Sequence_Listing_222552_602954.txt and is 66,802 bytes in size.
Pathogenic corona viruses (SARS, MRSA, SARS-nCov2) are single positive RNA strand viruses with a wide spectrum of hosts and a strong ability to mutate at high rate, spread rapidly by waste, contacts and aerosols, and only a very limited set of treatments are available to protect infected patients.
The “corona-like” virus structure itself consists of the positive strand RNA packaged into the core of the virus, said core comprising membrane proteins and the spike protein. Membrane proteins support the viral morphogenesis, and the spike protein is a glycoprotein that attaches the virion to the cell membrane by interacting with the host receptor, thereby initiating the infection of the cells.
Clearly, the spike proteins as well as the other viral proteins are under intense study and huge effort is made to develop new rational antiviral treatment as well as vaccines. Currently discussed, antiviral treatment and drug candidates are: Remdesivir (viral polymerase inhibitor), Umifenovir (Fusion inhibitor), Lopinavir (Retrovirus protease inhibitor), Ritonavir (Retrovirus protease inhibitor) and Hydroxychloroquine (anti malaria drug).
A common factor in all of the known antiviral drugs is that they are highly toxic. This is tolerable as long as the application is life saving or preventing a severely debilitating outcome of the diseases. In many cases, however, the viral disease symptoms that may trigger the treatment are mild and may remain mild, rendering the toxic antiviral drug too dangerous to apply, or the side effects in severe cases of the viral infection actually further hurt the patients that already suffer from lung, liver, and/or intestinal symptoms.
It is an object of the present invention to provide another therapeutic approach. Particularly the inventor analysed the known mechanism of the viral infection, the progress of the infection, and the response of the human body. Critical elements in the physiological response were identified in order to design new drug candidates that shall help the body to hinder the progress of the viral infection, stopping the debilitating side effects and consequences of the disease.
Disclosed herein is a therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders, wherein the therapeutic composition comprises at least one active agent being selected from the following active agent groups a) to e):
Further disclosed is a method of treating COVID-19 and other cytokine storm associated disorders, wherein said method comprises administering an effective amount of at least one active agent being selected from the abovementioned active agent groups a) to e).
As used herein, the term “therapeutic composition” refers to a composition to be administered as a therapeutic treament to a subject suffering from a disorder.
As used herein, the term “treatment” in the context of the administration to a subject refers to the reduction or inhibition of the progression and/or duration of disorder.
As used herein, the term “subject” refers to a mammal, most preferably a human.
As used herein, the term “composition” refers to an effective amount of one or more active agents, optionally in combination with pharmaceutical acceptable carriers and/or excipients.
By “pharmaceutically acceptable,” is meant a compound that is not biologically or otherwise undesirable, that is, the compound may be incorporated into a topical formulation of the invention and administered to a patient without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the formulation in which it is contained.
As used herein, the term “active agent” refers to a compound being effective in the treatment of a disorder, when being administered in an effective amount to a subject suffering from a disorder.
As used herein, the term “effective amount” refers to the amount of a treatment that is sufficient to result in the prevention of the development, recurrence, or onset of a condition being associated with a cytokine storm, and one or more symptoms thereof, to enhance or improve the prophylactic effect(s) of another therapy, reduce the severity, the duration of a cytokine storm associated disorder, ameliorate one or more symptoms of a condition being associated with a cytokine storm, prevent the advancement or recurrence of a cytokine storm, cause regression of a disorder being associated with a cytokine storm.
As used herein, the term “cytokine storm associated disorder” refers to a disorder that may result in a condition called “cytokine storm”. The cytokine storm is characterized by unusual high blood levels of cytokines, such as chemokines, interferons, interleukins, lymphokines as compared to the corresponding blood levels of said cytokines in a healthy subject. Particularly relevant are the blood levels of inflammatory cytokines interleukin-1 (IL-1), IL-6, IL-12, and IL-18, tumor necrosis factor alpha (TNF-α), interferon gamma (IFNγ), granulocyte-macrophage colony stimulating factor (GM-CSF) and Transforming Growth Factor (TGF).
If the blood level of at least one inflammatory cytokine is raised in a subject by more than 10%, more than 20% or even more than 30% as compared to the corresponding blood level(s) of said cytokine(s) in a healthy subject, this is an indicator for an onset or for the presence of a cytokine storm. If the blood level of two or more inflammatory cytokines is raised in a subject by more than 10%, more than 20% or even more than 30% as compared to the corresponding blood level(s) of said cytokine(s) in a healthy subject, this is an even more clear indicator for an onset or for the presence of a cytokine storm.
Cytokine storm may be induced by various instances, including but not limited to infection with SARS COV-2 virus, any other corona viruses and any hemorrhagic fever causing viruses. It may also be induced by other physiological states and disorders.
The term “cytokine storm associated disorder” includes any disorder of a subject, that may result in a “cytokine storm” to occur. Examples for cytokine storm associated disorders that may be treated in accordance with the present invention are COVID-19, Hemorrhagic fever diseases, Allergy, Alzheimer's disease in CNS, ARDS/respiratory distress, Bechet's disease, bronchial asthma, capillary leak syndrome, ischemia, ischemia-reperfusion, chronic lung disease, immunocomplex glomerulonephritis, Churg-Strauss syndrome, Cystic fibrosis, Mediterranean fever Guillain-Barre, Cardiac ischemia and infarct reperfusion, Kimura's disease, Multiple Sclerosis, MS Meningitis Pancreatitis, Preeclampsia, Retinitis, Allogenic graft rejection, chronic inflammation, septic shock, acute ischemia, trauma and surgery, cardiac pathology and multiple organ failure, allotransplantation, asthma, acute respiratory distress syndrome, arthus reaction, burns injuries, Crohn's disease, dermatomyositis, drug-induced pseudoallergy, Forssman shock, glomerulonephritis, hemolytic anemia, hemorrhagic shock, hemodialysis reactions, hereditary angeoderma, Huntington's disease, infertility as a result of spontaneous abortion, ischemia reperfusion injuries, human complex-induced vasculitis, multiple sclerosis, myasthenia gravis, Pick's disease, paroxysmal nocturnal hemoglobinuria, post-bypass syndrome, psoriasis, rheumatoid arthritis and septic shock.
The complement system is a part of the immune system. Over 30 proteins and protein fragments make up the complement system, including serum proteins, and cell membrane receptors. When stimulated by one of several triggers, proteases in the system cleave specific proteins to release cytokines and initiate an amplifying cascade of further cleavages. The end result of this complement activation or complement fixation cascade is stimulation of phagocytes to clear foreign and damaged material, inflammation to attract additional phagocytes, and activation of the cell-killing membrane attack complex.
Any process that activates the complement system goes through a series of positive feedback loops. Complement activation releases anaphylatoxins, C3a, C4a and C5a, all of which are powerful signaling molecules. The C5a gets mobilized, activated and released a substantial number of mediators. These factors in turn cause pulmonary hypertension, vascular dilation, together with the membrane attack complex cause vascular leakage, hypotension, hypoxia, acidosis, vasoconstriction, more hypoxia, intestinal symptoms and bacterial leakage, endotoxemia, fever, more complement activation, more granulocyte activation, more endothelial damage, and finally severe pulmonary hemorrhage, and cardiovascular damage. The major mediators of this process are the cytokines. Therefore, this process is also known as cytokine storm.
Once this cytokine storm is fully developed, it is irreversible, and most of the cases causes multiple organ failure, and death. Cytokine storm plays key role in cardiovascular-pulmonary collapse that is central element in death caused by hemorrhagic viruses, blood lost induced hemorrhagic shock, bacterial septic shock, pancreatitis, and most of systemic inflammatory shock diseases, drug-adverse reactions, CAR-T cell therapy adverse reactions. Further, it is known to be one of the reasons for many fatal cases of COVID-19.
The cytokine storm being a devastating medical disorder, it is disclosed a novel and effective treatment that reduces, diminishes and abolishes the devastating physiological effects of the cytokine storm. The goal of the treatment is avoiding immunosuppression while the cytokine storm is limited and remains at levels compatible with healing from the disease state that induced it.
Particularly, it is disclosed a treatment directed to a set of 5 targets participating in eliciting, amplifying and otherwise exacerbating the cytokine storm. These targets were rationally selected with expertise from hundreds of molecules participating in the onset and amplification of the cytokine storm.
It is disclosed a therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders. By comprising at least one active agent selected from the following active agent groups:
a) Complement Factor 3-Targeting Inhibitor of Complement Activation Cascade
The root cause of the cytokine storm is the rapid and out of control complement system activation and while the triggering factors counts in dozens, and each of them result in a protease activity called C3 convertase (embodied in various forms) sharing common feature to be capable of specifically cleaving the C3 (complement factor 3) into C3a and C3b components, creating an active C3b, that itself acts as a C3 convertase via the C3b cleavage product. Targeting C3 and preventing the positive feedback loop is the first target selected.
Therefore, the present invention encompasses a therapeutic composition comprising at least one complement factor 3-targeting inhibitor of complement activation cascade. In some embodiments the complement factor 3-targeting inhibitor is a direct inhibitor of the complement factor 3 receptor. In other embodiments the complement factor 3-targeting inhibitor is an inhibitor of the complement factor 3 receptor activity through reducing the release of C3a anaphylatoxin. By reducing the release of C3a anaphylatoxins the activity of the complement factor 3 receptor can be reduced indirectly, that is, without using direct complement receptor 3 inhibitors.
C3 is the central element of the complement activation pathway, and blocking excess C3 activation blocks all the anaphylatoxin production, including subsequent raise of the cytokine storm. However, according to one aspect of the invention, C3 and its activity shall not be eliminated completely, as it is essential for the protection from microbes and for development of proper immune reaction. This is why in some embodiments the complement factor 3-targeting inhibitor is an inhibitor of the complement factor 3 receptor activity through reducing the release of C3a anaphylatoxin. This allows better fine tuning of complement factor 3 receptor activity.
In order to provide a complement inhibitor that acts fast, reversibly and without accumulation of toxic byproduct, the inventor has analyzed the human C3 protein with a proprietary algorithm implemented in C language and designed a series of peptides that were tested for their ability for inhibiting complement activity in a hemolysis assay. The inventor found that out of a library of 19 peptides 7 peptides inhibited the complement of complement mediated hemolysis very strong (80% or higher inhibition), 4 peptides inhibited hemolysis strong (40% or higher inhibition), 5 peptides had moderate inhibitor activity (20% or higher inhibition) and 4 peptides had low inhibitor activity (less than 20% inhibition) under the test conditions.
Accordingly, in some embodiments of the inventive therapeutic composition the complement factor 3-targeting inhibitor of complement activation cascade of active agent group a) is selected from the following group of peptides:
The one letter code amino acid sequences and the hemolysis inhibition properties of said peptides are indicated in Table 1 of the examples further below.
b) Carboxypeptidase B Enzyme
Whenever there is complement activation, the cleavage of key components C3, C4 and C5 results in massive release of respective anaphylatoxins. Each of them is a single chain, 74 amino acid long amino terminal fragment of the respective complement factor (complement factor 3, 4 and 5), and each of them is terminated with an arginine amino acid at their carboxyterminal end. While all of them are powerful mediators, their activity is strongly diminished by the loss of the carboxy terminal arginine.
C5a is an effective chemoattractant, initiating accumulation of phagocytic cells at sites of infection or recruitment of antigen-presenting cells to lymph nodes. C5a also modulates the balance between activating versus inhibitory IgG Fc receptors on leukocytes by increasing it, thereby enhancing the (auto)immune response and triggering a genuine cytokine storm.
The anaphylatoxins and many of the messengers amplifying cytokine storm are peptides with an amino acid arginine at the carboxy terminus. The enzyme that removes that arginine renders the specific messengers and anaphylatoxins lose or reduce or change their biological activity. However, the inventor has found that this enzyme activity is very low in plasma. What is more, it is rapidly depleted as infection, hemorrhage, hypoxia develops, blood coagulation triggered (see Examples further below), in each case when systemic complement activation occurs, resulting in allowing anaphylatoxins to act at their full potential to trigger the positive feedback that results in Cytokine storm.
For removing the terminal arginine of peptides there is a set of enzymes called carboxypeptidase (E.C. numbers: 3.4.16 through 3.4.18), a subgroup consists of basic carboxypeptidases that specialize in removing basic amino acids Arg and Lys from the carboxy terminus of the peptide. It turned out that there is one enzyme specialized for converting C5a into desArg C5a. What is more, it has been shown that it is rapidly lost by self-inactivation.
Replenishing this enzyme, is expected to protect the patient from the excess power of these mediators, coagulation system malfunctions and granulocyte leukocyte activation and chemoattraction to the shock organs. Therefore, the present invention encompasses a therapeutic composition comprising at least carboxypeptidase B enzyme.
In some embodiments of the inventive therapeutic composition, said composition comprises as an active agent carboxypeptidase B enzyme being selected from the carboxypeptidases EC 3.4.16-3.4.18.
Further, the inventor has developed recombinant carboxypeptidase B enzymes having the amino acid sequences as specified in SEQ IDs No. 21-22. Said enzymes may be used in the treatment of cytokine associated disorders such as COVID-19. Therefore, in some embodiments of the inventive therapeutic composition said composition comprises as an active agent one of the aforementioned recombinant carboxypeptidase B enzymes. The one letter code amino acid sequences of said enzymes are indicated in the examples further below.
Said recombinant carboxypeptidase B enzyme can be obtained by a method comprising the following steps:
The present application also encompasses a nucleic acid encoding recombinant carboxypeptidase B enzyme. Further, it is disclosed a lentiviral vector comprising this nucleic acid. In addition, it is disclosed a plasmid comprising this nucleic acid and a cell line comprising said plasmid. Furthermore, it is disclosed a method of producing recombinant carboxypeptidase B enzyme by cultivating a cell comprising the plasmid.
c) Complement Factor 5a Receptor-Targeting Inhibitor of Complement Activation Cascade
By using one or both of the aforementioned active agents of groups a) and b), it is possible to control complement activation through inhibiting complement factor 3 and adding Carboxypeptidase B enzyme to keep the desArg form of the newly generated anaphylatoxins and disturbance in the coagulation system. This could significantly reduce the chance of the viral infection to turn into full cytokine storm.
However, a prolonged release and accumulation of C5a, even a very minuscule amounts on the site of the virus infection or tissue damage would still be able to activate attract and granulocytes and cause massive degranulation in the affected tissue, causing irreversible tissue damage. The C5a acting on its receptor is the main culprit in this process. It has been found that this receptor is one of the most sensitive receptors in cell signaling. The inventor has noted that picomolar quantities of C5a can trigger the intracellular activation signal and increase of Ca++ levels.
C5a is the most powerful of the anaphylatoxins, and it exerts massive effect on cell expressing its receptor. These cells are heavily involved in the cytokine storm and induce the production of a vast array of secondary messengers, regardless of C5a has or lacks the terminal arginine. The nature of the effect may change though, but if the receptor is blocked, the overactivation of the cells involved in triggering the cytokine storm may be blocked, and kept at acceptable level, not threatening the patient's life or tissue integrity.
Therefore, the present invention encompasses a therapeutic composition comprising at least one complement factor 5a receptor-targeting inhibitor of complement activation cascade involved in the cytokine storm induction. In some embodiments the complement factor 5a receptor-targeting inhibitor is an inhibitor of the complement factor 5a receptor. In some embodiments the complement factor 5a receptor-targeting inhibitor is a competitor of the complement factor 5a or a fragment thereof. In some embodiments the complement factor 5a targeting inhibitor is not a competitor for the binding sites for the complement factor 5a, but interacts in another way with the complement factor 5a receptor, thereby inhibiting complement activation cascade. The inventor has synthesized and tested a large number of peptide-based C5aR agonists and antagonists, both, in vitro and in vivo. However, in many cases the beneficial effects do not materialize to the required extent. Particularly, some of the inhibitory variants of the peptides are not sufficiently compete with naturally occurring level of C5a in vivo for the ligand binding.
In some embodiments of the present invention, the complement factor 5a receptor-targeting inhibitor of complement activation cascade of active agent group c) is selected from the group of peptides:
The one letter code amino acid sequences of said peptides are indicated in Table 3 of the examples further below. Said peptides have been shown to be very effective inhibitors of complement factor 5a receptor, both, in vitro and in vivo.
These peptides are considered potentially useful in clinical applications, but the observed biphasic activity of the most promising one (PR226), that it acted as inhibitor at high concentration and activator as low concentration, was a property that questioned the safety of the peptide for human use. However, the inventor has designed an oligomeric form of the peptide, a dendrimer, that increased its activity 10,000-fold, and the receptor inhibitory activity increased from femtomolar to 200 nM levels, a tremendous potential.
The activity in vivo, in rat and pig models, is shown in the examples below. Further, it has been shown that the peptide can be delivered in vivo very safely, even at very high concentration. The reason is that the peptide immediately binds to the erythrocyte surfaces and forms a stable membrane bound pool that is completely inert to erythrocytes, but upon contact with C5aR bearing cells, the inhibitory effect is fully exhibited. In addition, in the membrane bound state, the peptide remains active for at least 12 hours. Therefore, it is a very effective C5aR inhibitor.
d) Endothelin a Receptor-Targeting Inhibitor of Extravasation
The inventor has observed that activated macrophages and leukocytes do not do any harm while in the circulation. They do not act until they are surrounded by live, healthy erythrocytes. Particularly, they need to undergo extravasation, moving out of the capillaries into the affected tissue parenchyma.
Further, the inventor has identified that endothelin receptor is one of the bottleneck elements in the very complex and highly redundant process of extravasation. Particularly, the inventor noted that the process of extravasation is controlled by the endothelial cells. They open the gates upon the signal delivered by the endothelin peptide and engaging the endothelin A receptor on their surface. If said gates are not opened, the activated leukocytes cannot pass through the tightly bound endothelial membrane.
Therefore, the inventor has picked this as the fourth target in the treatment of cytokine storm. Particularly, the inventor has postulated that blocking extravasation could be the solution to down regulate the overactivated cells and prevent them from causing irreversible tissue damage.
Therefore, the present invention encompasses a therapeutic composition comprising at least one endothelin A receptor-targeting inhibitor of cytokine storm activation cascade. In some embodiments the endothelin A receptor-targeting inhibitor is an inhibitor of the endothelin A receptor. In some embodiments the endothelin A receptor-targeting inhibitor is a competitor of the endothelin A or a fragment thereof. In some embodiments the endothelin A targeting inhibitor interacts in another way with the endothelin A receptor and/or the endothelin A or a fragment thereof, thereby inhibiting complement activation cascade.
In some embodiments the endothelin A receptor-targeting inhibitor of extravasation is selected from the group of peptides:
The one letter code amino acid sequences of said peptides are indicated in Table 4 of the examples further below.
e) Bone Morphogenetic Protein (BMP)
Complete blocking of the cytokine storm may not be advised, especially in case of viral and bacterial infection, as it could result in an iatrogenic immunodeficiency, and allow the infectious agents to propagate uncontrolled, causing a devastating outcome of the disease.
The inventor has opted for two elements to remedy this issue: the first is that they have designed and selected effector molecules that do not accumulate and break down rapidly, allowing a rapid tuning of the status of the cytokine storm; and the second element is that an additional target should be included that helps to heal the internal wound, a tissue damage accompanied by cell death, tissue disorganization to be restored in an enhanced and supported manner, as well as delay the invasion on fibroblast, preventing the irreversible tissue scarring that lead to loss of function in the affected organ.
Viral cytotoxicity, the system of tissue specific general complement activation, the passing of granulocytes through the endothelial layers from the capillaries into the shock organ parenchyma and cytokine-induced endothelial disfunction individually and combined, cause massive loss of shock organ parenchyma cells, blood vessel integrity, and hemorrhage. In simple terms, this is a mechanism of making wounds inside the affected tissues in cytokine storm. With loss of tissue integrity, the organ becomes dysfunctional and in extreme cases that causes death. In less severe cases, the patients undergo a long process of wound healing. That process is slow, requires rebalancing of cytokines, and orchestrates the activity of stem cells, cell differentiation as well as invasion by various cell types, including fibroblasts. Unlike “standard” wounds, hemorrhaged tissues heal very slowly.
Fibroblasts appear very early in the hemorrhagic wounds, and cause fibrosis, scar formation that implies significant function loss in any affected organ. Fibrosis denotes excessive scarring, which exceeds the normal wound healing response to injury in tissues injured during cytokine storm.
It has been shown that bone morphogenetic proteins may regulate excess fibrosis. Therefore, in some embodiments of the present invention the therapeutic composition comprises a bone morphogenetic protein. In specific embodiments said bone morphogenetic protein is selected from bone morphogenetic protein BMP-6
Further, there are disclosed new recombinant bone morphogenetic proteins BMP and new active domains of bone morphogenetic proteins, and the specifications of said new recombinant bone morphogenetic proteins and the specifications of said new active domains of bone morphogenetic proteins are indicated in Tables 5 and 6 of the examples further below.
Therefore, in some embodiments of the present invention the therapeutic composition comprises a new recombinant bone morphogenetic protein BMP having an amino acid sequence as specified in one of the SEQ ID Nos. 38 to 40.
In further specific embodiments said recombinant bone morphogenetic protein is selected from a protein comprising an active domain having an amino acid sequence as specified in one of the SEQ ID Nos. 41 or 42 or from a protein comprising both of the two active domains having the amino acid sequences as specified in SEQ ID Nos. 41 and 42. Said protein may comprise in addition the specific leader sequences, hinge regions and anchor fragments as specified in table 6 below.
The present application also encompasses a nucleic acid encoding the recombinant bone morphogenetic proteins BMP. Further, it is disclosed a lentiviral vector comprising this nucleic acid. In addition, it is disclosed a plasmid comprising this nucleic acid and a cell line comprising said plasmid. Furthermore, it is disclosed a method of producing recombinant bone morphogenetic protein BMP by cultivating a cell comprising the plasmid.
In addition to the claimed composition, the present invention also encompasses a rationally designed method of treating a cytokine storm associated disorder. Particularly, it is disclosed a method of treating a cytokine storm associated disorder, characterized in that the method comprises administering an effective amount of at least one active agent selected from active agent groups a) to e):
The inventive method of treatment is a selection of a limited number or target molecules within the highly complex cascades of interrelated enzymes, mediators, and receptor and other proteins that when operating in concert, lead to the phenomenon known as cytokine storm.
Unlike general immune suppressions, depletion of complements system, plasmapheresis, irradiation and other interventions already in practice, this treatment leaves intact the functioning of the immune system, innate and antigen specific, essential to protection from the underlying viral or bacterial or fungal infections while enabling the fine tuning of the level of the functions necessary for the protective immunity by designing tools that are very short lived in the system and makes dangerous overdosing essentially impossible, as the active compounds (peptides and auto inactivating or naturally degrading proteins) never accumulate, rapidly clear from the circulations in hours, restoring the full functioning of the immune system and all of its components instantaneously.
The treatment consists of any one of the active components, any combination of two of the active components, any combination of 3 of active components, any combination of 4 active components, all 5 components of the active components that are intended to remedy the abnormality of the targets involved in the cytokine storm.
Particularly, it is disclosed a treatment or therapeutic composition for use in the treatment of COVID-19 and other cytokine storm associated disorders including either:
The therapeutic composition of the present invention provides means for effectively treating COVID-19 and other cytokine storm associated disorders. In some embodiments of the invention the therapeutic composition used comprises at least two, three, four or five distinct active agents being selected from at least two, three, four or five of the active agent groups a) to e).
The treatment includes in some embodiments a formulation for delivery as a pH stabilized infusion that counteracts potential tissue acidification. In some embodiments the inventive composition is formulated with antiviral, anti-microbial agents. The inventive composition may be delivered as preventative intervention or as treatment for destructive cytokine storm.
The delivery of the active compounds of the treatment for controlling the cytokine storm may coincide with the need to use optional factors, depending on the root cause of the cytokine storm. Since the treatment coincides with the treatment of the root cause, we include additional supporting material to be added in the final embodiment of the invention.
After selecting the targets, the inventor has designed and developed a series of highly specific compounds that meet the needs envisioned for the treatment of the overactive cytokine storm and break its positive feedback loops as well as moderate the tissue damage that it causes in the affected patients.
As an additional requirement, the inventor selected a series of solution relaying on short lived compound that do not accumulate, break down naturally without leaving potentially toxic molecules behind.
a) Complement Factor 3-Targeting Inhibitor of Complement Activation Cascade for Target 1
The inventor has designed a series of 19 peptides using a proprietary algorithm and the material composition is presented in table 1 below.
The peptides were synthesized by Fmoc solid phase method, purified on C18 reversa phase chromatography, tested by adding each peptide to and screened for complement inhibitory activity, in a simple antibody dependent hemolysis system in which 1 ug/mL of peptides were added to guinea pig complement, and were titrated against turkey erythrocytes mixed with hemolysin, a complement fixing anti-erythrocyte antibody solution. In the presence the peptides, the hemolythic activity of the complement was reduced, and the corresponding dilutions was determined. The inhibition was estimated by a formula:
Inhibition (%)=100−(dilution of sample titer*100)/dilution of control
b) Carboxypeptidase B Enzyme for the Target 2
By rapid activation of carboxypeptidase B with trypsin, the inventor has found that the carboxypeptidase B enzyme activity is very low in plasma. What is more, it is rapidly depleted as infection, hemorrhage, hypoxia develops, blood coagulation triggered (cf.
Further experiments indicated that, in rats, the carboxypeptidase B activity is completely depleted during the early phase of hemorrhagic shock model in rats (in 100 minutes it is reduced nondetectable levels). Providing external carboxypeptidase B and restoring the depletion could significantly slow down the events leading to the onset of lethal cytokine storm.
To replenish the carboxypeptidase pool, the inventor designed a recombinant human zinc-metalloproteinase, using the gene for pre-procarboxypeptidase B, encoded by cpb1 gene. The deduced protein the inventor edited the deduced protein sequence, replaced the promoter with a proprietary one that is optimizes for fast and effective secretion of the preproprotein, and introduced a mutation that replaced the original T with a N amino acid at the activation cleavage site and reduced the intracellular toxicity of the preproprotein that enables the overexpression with rapid secretion and results in high yield production. The inventor left the internal inactivation site intact, therefore retained the expected natural inactivation times.
In another embodiment of the invention, human carboxypeptidase B2 (TAFI) is used for its highly similar enzyme activity. This enzyme has been reengineered in order to add a novel, improved secretory peptide, reduced the strength of its activation signal that is needed to convert the pre pro enzyme into an active enzyme as well as reduced the availability of the cryptic tryptic cleavage site in order to prolong its half life in the serum.
In the case of carboxypeptidase B1, the sequence was reverse translated into DNA and optimized for high yield overexpression in DG44 cells. A standard EF1 promoter was added for high efficiently and constitutive expression and built into a payload plasmid that is used for making a lentiviral expression vector to transduce a cell line.
The expression cassette designed for the recombinant human carboxypeptidase preproprotein expression is shown in
The detailed specification of the obtained recombinant human carboxypeptidase B1 and B2 carboxypeptidase enzymes are shown in tables 2a and 2b below.
YTRAKS
KDHEELSLVA
LRDTGTYGFLLPERYI
The antisense homology box peptide corresponding to region 10-27 in the C5a receptor PR10 (DYGHYDDKDTLDLNTPVD; SEQ ID No. 26) did not inhibit the receptor activity, although it was demonstrated that it bound to two of its corresponding antisense peptides derived from C5a anaphylatoxin: peptides corresponding to amino acids 37-43 and 61-74.
The antisense homology box peptide PR101 (HWPFGGAACSILPSLI, SEQ ID No. 27, Mw: 1782 corresponding to region 10-27 in the C5a receptor) did not affect the C5a-induced Ca++ influx; however, it was found that this peptide strongly interacted with the albumin present in the culture medium causing its precipitation and aggregation.
A peptide fragment of the C5a receptor corresponding to the loop between the fifth and sixth hypothetical transmembrane regions (amino acids 226-245) that is antisense to C5a and is an intramolecular AHB in C5a receptor proved to be a weak antagonist of C5a when preincubated with C5a at high concentrations (>0.5 μM). It was shown by its ability to inhibit Ca++ influx induced by C5a anaphylatoxin in C5a receptor-expressing (cAMP stimulated) U937 cells.
The same peptide fragment was shown to have C5a agonist activity as well, when U937 cells bearing the C5a receptor were preincubated with this peptide at a much lower concentration (even as little as 40 pM), the AHB peptide behaved as an agonist: Ca++ influx was efficiently triggered, even in the presence of an otherwise ineffective amount of C5a.
The AHB peptides derived from C5a anaphylatoxin, PL3 (QKKIEEIAAKYKHS, SEQ ID No. 52, Mw: 1670, C5a amino acids 3-16), PL12 (KYKHSVVKKSDGA, SEQ ID No. 53, Mw: 1801, C5a amino acids 12-27), PL37 (RAARISLGPRSIKAFTE, SEQ ID No. 54, Mw: 1985, C5a amino acids 37-51) and PL61 (LRANISHKDMQLGR, SEQ ID No. 55, Mw: 1740, C5a amino acids 61-74), were not able to inhibit C5a receptor in C5a-induced Ca++ influx assay.
The present invention includes methods and compositions that are designed to disable the ability of the C5a receptor to transmit cellular signals that are produced by binding of C5a to the receptor. One embodiment of the present invention is an inhibitory oligomer of peptides. One embodiment of the present invention consists of four repeats, the second consist of 8 monomers, collectively forming dendomer structure.
One specific monomer is a peptide of 17 amino acid long sequence derived from the C5a receptor itself. Each of the four monomers individually has a complex helical structure that forms spontaneously after the peptide is synthesized. Thus, the linear sequence of amino acids of each of the monomers which is manufactured in a peptide synthesizer at low cost, forms by itself into a more complex 3-dimensional structure, and the four or eight monomers are assembled during manufacture as a tetramer or octamer, or synthesized using a core in the form of
It is to be understood that although an oligomer with four repeats of the peptide is the most desired form of the present invention, oligomers with 2 through 16 repeats of the peptide are also affective in inhibiting C5a receptors. Another embodiment of the oligomer is the octameric repeat of the peptide.
Because of the particularly folded conformation of each monomer, and because of the additive effects of the four monomers, the tetramer fits perfectly with high affinity within the inner folded structure of the C5a receptor and blocks the ability of the receptor to induce damaging biological effects. The damaging caused by C5a effects that can be prevented by this compound include: the activation of granulocytes and release of tissue-injuring enzymes, constriction of blood vessels and capillaries which severely restrict the perfusion of tissues by blood, inflammation that changes vascular permeability, causes edema, attracts cells which in turn provoke severe tissue damage, and other effects that promote acute extension of myocardial infarcts.
The present invention is a C5a inhibitor that is differentiated from other products that inhibit C5a activity (such as antibodies or other proteins or peptides), that this construct will not only bind to C5a, reducing and neutralizing the available amount of C5a, but in the same time it binds to the C5a receptor, inhibiting its activity as a true C5a receptor inhibitor as well. This double-sided activity results in extremely powerful and efficient C5a inhibitor in that it substantially inactivates the C5a receptor's ability to function as a receptor. Other strategies currently being developed attempt to compete with C5a for binding to the receptor. A beneficial consequence of the present invention is the requirement of a very low effective concentration of the inhibitor to prolong the term of prevention of the damage caused by C5a by prolonged disabling of the receptors ability to function, while the low concentration of the present invention minimizes the potential side effects.
A distinct advantage of the present invention is that, because it inactivates the receptor itself, its effectiveness is not influenced by the local concentration of C5a. The inhibitor peptide is effective even in the presence of massive amounts of C5a that are typically generated during complement activation in the course of a heart attack or other adverse event. Other strategies that simply compete with C5a for binding to the C5a receptor can be overcome simply by increasing the local concentration of C5a to overwhelm the inhibitor. This inhibitor does not affect C5a binding and does not compete with the receptor-ligand interaction, rather affects the conformation of the C5aR and blocks its ability to transfer stimulatory information into the cell.
In
Further, it has been shown that the peptide can be delivered in vivo very safely, even at very high concentration. In
d) The Endothelin Receptor Inhibitors for Target 4
The endothelin receptor is a complex of seven transmembrane helices and loops connecting them and belong to the family of the G-protein associated receptors the same family of receptors the C5a receptor is also a member. The inventor has run similar analysis and identified several antisense homology box peptides, using the same proprietary algorithm, and synthesis process (FMOC solid phase synthesis). The peptides and their variants have been produced and tested in standard functional endothelin assay in which external endothelin is added to prepared smooth muscles cells and the endothelin induced muscle contractility was measured. The peptides that inhibit the signal transduction by the receptor, are identified as Endothelin receptor inhibitors and are listed in Table 4 by their peptide ID, the amino acid sequence and their referenced name in the art.
One of the peptides was subsequently tested in dogs and confirmed its biological effect in vivo. Injecting dogs iv with 50 nm of ET-1 peptide resulted in a rapid increase in the concentration of the peptide: the normal baseline values of 2-3 fM increased to as high as 10-15 fM within 1 min and remained at high level for at least 10 min, followed by slow but steady decrease, but even after 30 min, the circulating endothelin level exceeded 6-7 fM. The elevated ET-1 level was marked with profound changes in circulation (details to be published elsewhere). However, pretreatment of dogs with 100 ug/kg ETR-P1/fl peptide removed the cardiovascular effects of injected ET-1 peptide from the circulation within 10 min and the measured endothelin level become normal. In spite of strong “buffering” effect of ETR-P141 peptide on externally administered ET-1 our data indicate that the peptide had a little or no influence (except a transient, 30-50% decrease) on the normal baseline level of ET peptide in the plasma. The explanation of this finding is that this peptide changed the conformation of the endothelin receptor, and that became capable of binding 4 times more ET-1 peptide, while frozen in an inactive conformation as far as receptor activation is concerned, indicating its high specificity, potency and stability that it can be applied in vivo. It is known in the previous art and has been patented and the patent expired.
The inventor also found that endothelin A receptor-targeting inhibitor of extravasation peptides do actively prevent leukocyte extravasation from circulation when stimulated by ET-1 in experimental system induced firm leukocyte adherence throughout the 90-minute observation period in animal models. The ETB-receptor antagonist IRL 1038 did not influence the number of sticking leukocytes in the submucosal postcapillary venules but transiently reduced the number of stickers in the collecting venules 30 minutes after ET-1 administration.
e) The Recombinant Bone Morphogenetic Protein 6 for Target 5
By screening over 30,000 clones including the unmodified BMP6 expression system a 2-5 mg/L volumetric yield could be achieved. Therefore, the inventor designed a recombinant bone morphogenetic protein combining the fibroblast blocking and wound healing promoting effect of BMP 6 by molecular engineering. The protein was modified with novel leader peptide that was developed by the inventor. This new leader peptide improves secretion 4 times. Further, a modified activation site was engineered that reduces the activation and prevents the enzyme to be activated inside the cells and reduces its toxicity when overexpressed. With these modifications, extraordinary expression rates were achieved. Particularly, by screening of less than 180 clones, including the new recombinant bone morphogenetic protein, over 1 g/L volumetric productivity was achieved in a bioreactor. This allows the production of over 500-1000 purified human doses in a single mL of supernatant.
The expression cassette designed for the recombinant bone morphogenetic protein is shown in
The material composition of the recombinant human Bone morphogenetic protein 6 (BMP6) has been improved by adding an optimized promoter and editing the sequence to reduce self-activation and the subsequent spontaneous inactivation of the protein by introducing a novel mutation at the activation site RRQQ→RRQA (SEQ ID Nos: 61 and 62, respectively).
Further, secretory and membrane attached forms of the recombinant human Bone Morphogenetic protein have been constructed.
QQSRNRSTQSQDVARVSSASDY
NSSELKTACRKHELYVSFQDLG
WQDWIIAPKGYAANYCDGECSF
PLNAHMNATNHAIVQTLVHLMN
PEYVPKPCCAPTKLNAISVLYF
DDNSNVILKKYRNMVVRACGCH
RVSSASDYNSSELKTACRKHEL
YVSFQDLGWQDWIIAPKGYAAN
YCDGECSFPLNAHMNATNHAIV
QTLVHLMNPEYVPKPCCAPTKL
NAISVLYFDDNSNVILKKYRNM
VVRACGCH
QSRNRSTQSQDVARVSSASDYN
SSELKTACRKHELYVSFQDLGW
QDWIIAPKGYAANYCDGECSFP
LNAHMNATNHAIVQTLVHLMNP
EYVPKPCCAPTKLNAISVLYFD
DNSNVILKKYRNMVVRACGCHR
The inventive peptides disclosed herein are defined by their amino acid sequence as presented respectively. The present invention also includes the following modifications thereof.
Qa—place amino acids here-Qc″, wherein Q″ is selected from the group consisting of hydrogen, alkyl, aryl, arylalkyl, alkyloyl, aryloyl, arylalkyloyl, alkyloxoyl, aryloxoyl and arylalkyloxoyl; and QC is selected from the group consisting of hydroxy, alky loxy, aryloxy, arylalkyloxy, alkylamino, dialkylamino, ary lamino, diarylamino, (aryl)(alkyl)amino, arylalkylamino, diarylalkylamino, (alkyl)(arylalkyl)amino, (aryl)(arylalky l)amino, and amino. Preferably Qa″ is hydrogen and QC is hydroxy, i.e., H—place amino acids here —OH. Preferably Q″ is H3C—C(O)— and QC is amino, i.e., H3C—C(O)—place amino acids here —NHZ. In another embodiment of the invention, the anti-wrinkle agent is a peptide having the amino acid sequence Qa-amino acids-Q″, wherein Q″ is selected from the group. In addition a peptide can be synthesis in dendromer form, where the peptide is described by the (Qa-place amino acids here-Q)8K4K2K-x formula of dendromeric branching structure. With Qa consisting of hydrogen, alkyl, aryl, arylalkyl, alkyloyl, ary˜loyl, arylalkyloyl, alkyloxoyl, aryloxoyl and arylalkyloxoyl; and QC is selected from the group consisting of hydroxy, alkyloxy, aryloxy, arylalkyloxy, alkylamino, dialkylamino, arylamino, diarylarnino, (aryl)(alkyl)amino, arylalkylamino, diarylalkylamino, (alkyl)(arylalkyl)amino, (aryl)(arylalky l)amino, and amino. Preferably Qa, is hydrogen and QC is hydroxy
To obtain the proper list of derivatives, replace the place holder amino acid sequence with each the listed amino acid sequence of the inhibitor peptides claimed in this invention.
As used herein, “alkyl” and “R” mean a hydrocarbon chain which may be straight, or branched; substituted (mono- or pot y-) or unsubstituted, preferably unsubstituted; saturated or monounsaturated (i.e., one double or triple bond in the chain), or polyunsaturated (i.e., two or more double bonds in the chain, two or more triple bonds in the chain, or one or more double and one or more triple bonds in the chain). As used herein, “aryl” and “Ar” mean an aromatic; substituted (mono- or poly-) or unsubstituted, preferably unsubstituted. Preferred aryls are phenyl, pyridyl, pynnidyl and napthyl; more preferred is phenyl. As used herein, “arylalkyl” means Ar—R—. As used herein, “alkyloyl” means R—C(O)— As used herein, “aryloyY” means Ar—C(O). As used herein, “arylalkyloyl” means Ar—R—C(O)—. As used herein, “alkyloxoyl” means R—O—C(O)—. As used herein, “aryloxoyl” means Ar—O—C(O)—. As used herein, “arylalkyloxoyl” means Ar—R—O—C(O)—. As used herein, “alkyloxy” means R—O—. As used herein, “aryloxy” means Ar—O—. As used herein, “arylalkyloxy” means Ar—R—O—. As used herein, “alkylamino” means R—N(H). As used herein, “dialkylamino” means R2N—. As used herein, “arylamino” means Ar—N(H)—. As used herein, “diarylamino” means (Ar)2N—. As used herein, “(aryl)(alkyl)amino” means Ar—N(R)—. As used herein, “arylalkylamino” means Ar—R— N(H)—. As used herein, “diarylalkylamino” means (Ar—R)2N—. As used herein, “(alkyl)(arylalkyl) amino” means Ar—R—N(R)—. As used herein, “(aryl)(arylalkyl)amino” means Ar—R—N(R)—.
| Number | Name | Date | Kind |
|---|---|---|---|
| 4079125 | Sipos | Mar 1978 | A |
| 4171299 | Hamburger | Oct 1979 | A |
| 4692511 | Hahn | Sep 1987 | A |
| 5011825 | Konig et al. | Apr 1991 | A |
| 5171739 | Scott et al. | Dec 1992 | A |
| 5547939 | Selsted | Aug 1996 | A |
| 5614370 | Konteatis et al. | Mar 1997 | A |
| 5807824 | van Oostrum et al. | Sep 1998 | A |
| 5837499 | van Oostrum et al. | Nov 1998 | A |
| 5837686 | Kirby et al. | Nov 1998 | A |
| 5849297 | Harrison | Dec 1998 | A |
| 5948668 | Hartman | Sep 1999 | A |
| 7553931 | Kolln | Jun 2009 | B2 |
| 7763708 | Okada et al. | Jul 2010 | B2 |
| 7786084 | Benner et al. | Aug 2010 | B2 |
| 9289467 | Lin et al. | Mar 2016 | B2 |
| 9907838 | Kim | Mar 2018 | B2 |
| 10238735 | Bredehorst | Mar 2019 | B2 |
| 20050154191 | Steward | Jul 2005 | A1 |
| 20060234921 | Shiels et al. | Oct 2006 | A1 |
| 20060275826 | Okada et al. | Dec 2006 | A1 |
| 20080161232 | Hummel et al. | Jul 2008 | A1 |
| 20080220003 | Schnatbaum et al. | Sep 2008 | A1 |
| 20140371133 | Francois et al. | Dec 2014 | A1 |
| 20160082089 | Kim | Mar 2016 | A1 |
| 20190328865 | Du | Oct 2019 | A1 |
| Number | Date | Country |
|---|---|---|
| 628910 | Sep 1992 | AU |
| 2003215446 | Mar 2009 | AU |
| 103796667 | May 2014 | CN |
| 1739078 | Jan 2007 | EP |
| 1 739 078 | Sep 2020 | EP |
| 900100052 | Jun 1991 | GR |
| 2003-313200 | Nov 2003 | JP |
| 2008526915 | Jul 2008 | JP |
| 1653980 | Mar 2019 | TW |
| WO-9009162 | Aug 1990 | WO |
| WO-92012168 | Jul 1992 | WO |
| WO-92021361 | Dec 1992 | WO |
| WO-93011153 | Jun 1993 | WO |
| WO-93011784 | Jun 1993 | WO |
| WO-9701578 | Jan 1997 | WO |
| WO-03086448 | Oct 2003 | WO |
| Entry |
|---|
| GenBank AAA85332.1, Complement component C3 [Homo sapiens], GenBank AAA85332.1, NCBI.NLM.NIH.GOV, 2 pages (Jan. 10, 1996), also available at https://www.ncbi.nlm.nih.gov/protein/AAA85332.1 (Year: 1996). |
| Bialy et at., Formulation, Delivery and Stability of Bone Morphogenetic Proteins for Effective Bone Regeneration, Pharm Res, vol. 34:1152-1170 (Mar. 24, 2017) (Year: 2017). |
| Nilsson et al., Neoantigens in complement component C3 as detected by monoclonal antibodies, Biochem. J., vol. 268:55-61 (1990); (Year: 1990). |
| Baranyi et al., The antisense homology box: A new motif within proteins that encodes biologically active peptides, Nature Medicine, vol. 1(9):894-901 (Sep. 1995) (Year: 1995). |
| Zhang et al., Absence of complement component 3 does not prevent classical pathway-mediated hemolysis, Blood Advances, vol. 3 (12):1808-1814 (Jun. 25, 2019) (Year: 2019). |
| Dhingra et al., Kimura disease: case report and brief review of the literature; Medicine and Pharmacy Reports, vol. 92(2):195-199 (Apr. 25, 2019) (Year: 2019). |
| Harris et al., Expanding horizons in complement drug discovery: challenges and emerging strategies, Semin. Immunopathol., vol. 40:125-140 (Oct. 6, 2017) (Year: 2017). |
| Carpanini et al., Therapeutic Inhibition of the Complement System in Diseases of the Central Nervous System, Frontiers in Immunology, vol. 10(article 362):1-17 (Mar. 4, 2019) (Year: 2019). |
| Asai et al., “Procarboxypeptidase R Deficiency Causes Increased Lethality in Concanavalin A-Induced Hepatitis in Female Mice,” Biol. Pharm. Bull. 2010, vol. 33, No. 7, pp. 1256-1259. |
| Baranyi et al., “Antisense homology boxes in C5a receptor and C5a anaphylatoxin: a new method for identification of potentially active peptides,” The Journal of Immunology, 1996, vol. 157, pp. 4591-4601. |
| Baranyi et al., “The antisense homology box: A new motif within proteins that encodes biologically active peptides,” Nature Medicine, Sep. 1995, vol. 1, No. 9, pp. 894-901. |
| Baranyi et al., “Antisense homology boxes coincide with the ”hot spot“ regions predicted by resonant recognition theory,” 2nd International Conference on Bioelectromagnetism , Feb. 1998, Melbourne Australia, pp. 67-68. |
| Baranyi et al., “Membrane-bound complement regulatory activity is decreased on vaccinia virus-infected cells,” Clin. Exp. Immunol. 1994, vol. 98, pp. 134-139. |
| Cook et al., “Structure of human desArg-C5a,” Acta Cryst. 2010, D66, pp. 190-197. |
| Farkas et al., “Complement C5a Receptor-Mediated Signaling May Be Involved in Neurodegeneration in Alzheimer's Disease,” The Journal of Immunology 2003, vol. 170, pp. 5764-5771; doi:10.4049/jimmunol.170.11.5764; http://www.jimmunol.org/content/170/11/5764. |
| Farkas et al., “A complement C5a fragment peptide causes apoptosis in TGW neuroblastoma cells,” 1996, Fifth International Conference On Alzheimer's Disease, S183. |
| Szebeni et al., “Hypersensitivity To Taxol and Doxil: Experimental and Clinical Evidence for a Causal Role of Complement Activation,” Circulation 1999, vol. 99, p. 2302. |
| Kazatchkine et al., “Activation of the complement system at the interface between blood and artificial surfaces,” Biomaterials, Jan. 1998, vol. 9, pp. 30-35. |
| Maglakelidze et al., “A Review: Does Complement or the Contact System Have a Role in Protection or Pathogenesis of COVID-19?” Pulm Ther May 13, 2020; https://doi.org/10.1007/s41030-020-00118-5. |
| Rathbone et al., “A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS),” 2013, BMJ Open 2013;3:e003573. doi:10.1136/bmjopen-2013-003573. |
| Sato et al., “Pro-Carboxypeptidase R is an Acute Phase Protein in the Mouse, Whereas Carboxypeptidase N Is Not,” J Immunol 2000, vol. 165, pp. 1053-1058. doi. 10.4049/jimmunol.165.2.1053; http://www.jimmunol.org/content/165/2/1053. |
| Szebeni et al., Role of Complement Activation in Hypersensitivity Reactions To Doxil and Hynic PEG Liposomes: Experimental and Clinical Studies, Journal of Liposome Research 2002, vol. 12 (1&2), pp. 165-172. |
| Szebeni et al., “Hemodynamic Changes Induced by Liposomes and Liposome-Encapsulated Hemoglobin in Pigs; A Model for Pseudoallergic Cardiopulmonary Reactions to Liposomes: Role of Complement and Inhibition by Soluble CR1 and Anti-C5a Antibody,” Circulation 1999, vol. 99, pp. 2302-2309. |
| Szebeni et al., “Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction,” American Journal of Physiology-Heart and Circulatory Physiology 2000, vol. 279, Issue 3; pp. H1319-H1328. |
| Campbell et al., “Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis,” Immunological Reviews 2001, vol. 180, pp. 162-167. |
| Zeisberg et al., “Are there endogenous molecules that protect kidneys from injury? The case for bone morphogenic protein-7 (BMP-7),” Nephrol Dial Transplant 2004, vol. 19, pp. 759-761; doi: 10.1093/ndt/gfh060. |
| Dituri et al. The Interactivity between TGFβ and BMP Signaling in Organogenesis, Fibrosis, and Cancer. Cells. 2019;8(10):1130. Published Sep. 23, 2019. doi:10.3390/cells8101130, Sep. 10, 2020 [reference “H” in IDS filed Sep. 10, 2020]. |
| Fletcher-Sandersjöö et al. Does Complement-Mediated Hemostatic Disturbance Occur in Traumatic Brain Injury? A Literature Review and Observational Study Protocol. Int J Mol Sci. 2020;21(5):1596. Published Feb. 26, 2020. doi:10.3390/ijms21051596, Sep. 10, 2020 [reference “J” in IDS filed Sep. 10, 2020]. |
| Kay et al. Distribution, dynamics and functional roles of phosphatidylserine within the cell. Cell Commun Signal 17, 126 (2019). Published Oct. 15, 2019 https://doi.org/10.1186/s12964-019-0438-z, Sep. 10, 2020 [reference “M” in IDS filed Sep. 10, 2020]. |
| Nagata et al. Flippase and scramblase for phosphatidylserine exposure. Curr Opin Immunol. Feb. 2020;62:31-38. doi: 10.1016/j.coi.2019.11.009. Epub Dec. 11, 2019. PMID: 31837595, Sep. 10, 2020 [reference “P” in IDS filed Sep. 10, 2020]. |
| Szebeni et a. Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions. Biomedicines. 2020;8(4):82. Published Apr. 8, 2020. doi:10.3390/biomedicines8040082, Sep. 10, 2020 [reference “V” in IDS filed Sep. 10, 2020]. |
| Vreede et al. Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Curr Opin Rheumatol. May 2019;31(3):231-240. doi: 10.1097/BOR.0000000000000595. PMID: 30747734; PMCID: PMC6455093, Sep. 10, 2020 [reference “W” in IDS filed Sep. 10, 2020]. |
| Waisayarat et a1. Intracardiac thrombus in a patient with catastrophic antiphospholipid syndrome: an autopsy case report and review of the literature. Vasc Health Risk Manag. 2019;15:253-258. Published Aug. 7, 2019. doi:10.2147/VHRM.S197638, Sep. 10, 2020 [reference “X” in IDS filed Sep. 10, 2020]. |
| Ramlall et aL. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med 26, 1609-1615 (2020). Published Aug. 3, 2020. https://doi.org/10.1038/s41591-020-1021-2, Sep. 10, 2020 [reference “AA” in IDS filed Sep. 10, 2020]. |
| Partial European search report dated Dec. 21, 2020 issued in European patent application No. 20185556.6. |
| Mahmudpour M. et al., “COVID-19 cytokine storm: The anger of inflammation”, Cytokine, Academic Press Ltd, Philadelphia, PA, US, vol. 133, May 30, 2020 (May 30, 2020), XP086227981, ISSN: 1043-4666, DOI: 10.1016/J.CYTO.2020.155151. |
| Huber-Lang, M. et al., “Double Blockade of CD14 and Complement C5 Abolishes the Cytokine Storm and Improves Morbidity and Survival in Polymicrobial Sepsis in Mice”, The Journal of Immunology, vo. 192, No. 11, Apr. 30, 2014 (Apr. 30, 2014), pp. 5324-5331; XP055758570, US ISSN 0022-1767, DOI: https://doi.org/10.4049.jimmunol.1400341. |
| Dituri et al. The Interactivity between TGFβ and BMP Signaling in Organogenesis, Fibrosis, and Cancer. Cells. 2019;8(10):1130. Published Sep. 23, 2019. doi:10.3390/cells8101130. |
| Fletcher-Sandersjöö et al. Does Complement-Mediated Hemostatic Disturbance Occur in Traumatic Brain Injury? A Literature Review and Observational Study Protocol. Int J Mol Sci. 2020;21(5):1596. Published Feb. 26, 2020. doi:10.3390/ijms21051596. |
| Kay et al. Distribution, dynamics and functional roles of phosphatidylserine within the cell. Cell Commun Signal 17, 126 (2019). Published Oct. 15, 2019 https://doi.org/10.1186/s12964-019-0438-z. |
| Nagata et al. Flippase and scramblase for phosphatidylserine exposure. Curr Opin Immunol. Feb. 2020;62:31-38. doi: 10.1016/j.coi.2019.11.009. Epub Dec. 11, 2019. PMID: 31837595. |
| Szebeni et a. Human Clinical Relevance of the Porcine Model of Pseudoallergic Infusion Reactions. Biomedicines. 2020;8(4):82. Published Apr. 8, 2020. doi:10.3390/biomedicines8040082. |
| Vreede et al. Cryptic conspirators: a conversation about thrombocytopenia and antiphospholipid syndrome. Curr Opin Rheumatol. May 2019;31(3):231-240. doi: 10.1097/BOR.0000000000000595. PMID: 30747734; PMCID: PMC6455093. |
| Waisayarat et al. Intracardiac thrombus in a patient with catastrophic antiphospholipid syndrome: an autopsy case report and review of the literature. Vasc Health Risk Manag. 2019;15:253-258. Published Aug. 7, 2019. doi:10.2147/VHRM.S197638. |
| Ramlall et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat Med 26, 1609-1615 (2020). Published Aug. 3, 2020. https://doi.org/10.1038/s41591-020-1021-2. |
| “Coronavirus: Hungarian Scientist Develops Medication against Cytokine Storm.” MTI—Hungary Today, May 6, 2020. [retrieved on Sep. 13, 2021]. Retrieved from the Internet: <URL: https://hungarytoday.hu/coronavirus-hungarian-scientist-develops-medication-against-cytokine-storm/>. |
| Farkas et al. C5a receptor expression by TGW neuroblastoma cells. Neuroreport. Sep. 29, 1999;10(14): 3021-3025, Abstract only. |
| Farkas et al. A neuronal C5a receptor and an associated apoptotic signal transduction pathway. J Physiol. 1998;507 ( Pt 3)(Pt 3):679-687. doi:10.1111/j.1469-7793.1998.679bs.x. |
| Kaneko et al. Antagonistic peptides against human anaphylatoxin C5a. Immunology vol. 86,1 (1995): 149-54. |
| Number | Date | Country | |
|---|---|---|---|
| 20210386821 A1 | Dec 2021 | US |
